A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor

Frontiers in Genetics

Volumn 4, Issue NOV, 2013, Pages

  Lubieniecka, Joanna M ^a,b   Graham, Jinko ^b   Heffner, Daniel ^a   Mottus, Randy ^a   Reid, Ronald ^a   Hogge, Donna ^a,c   Grigliatti, Tom A ^a   Riggs, Wayne K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Acute myeloid leukemia; Adverse drug reactions; Anthracycline induced cardiotoxicity; Complex trait; Daunorubicin; Global test; P450 oxidoreductase variants

Indexed keywords

EID: 84890306213     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00231     Document Type: Article

References (52)

1. Abecasis, G. R., Altshuler, D., Auton, A., Brooks, L. D., Durbin, R. M., Gibbs, R. A., et al. (2010). A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073. doi: 10.1038/nature09534.
2. Amin, N., Van Duijn, C. M., and Janssens, A. C. (2009). Genetic scoring analysis: a way forward in genome wide association studies? Eur. J. Epidemiol. 24, 585-587. doi: 10.1007/s10654-009-9387-y.
3. Bachur, N. R., Gordon, S. L., Gee, M. V., and Kon, H. (1979). NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. U.S.A. 76, 954-957. doi: 10.1073/pnas.76.2.954.
4. Barrett, J. C. (2009). Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb. Protoc. 2009, pdb ip71. doi: 10.1101/pdb.ip71.
5. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodol.) 57, 289-300.
6. Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I., Davies, S. M., Relling, M. V., et al. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112, 2789-2795. doi: 10.1002/cncr.23534.
7. Blanco, J. G., Sun, C. L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., et al. (2012). Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J. Clin. Oncol. 30, 1415-1421. doi: 10.1200/JCO.2011.34.8987.
8. Browning, B. L., and Browning, S. R. (2009). A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84, 210-223. doi: 10.1016/j.ajhg.2009.01.005.
9. Cowper-Sal Lari, R., Zhang, X., Wright, J. B., Bailey, S. D., Cole, M. D., Eeckhoute, J., et al. (2012). Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44, 1191-1198. doi: 10.1038/ng.2416.
10. De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2010). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121, 276-292. doi: 10.1161/CIRCULATIONAHA.109.895771.
11. De Bakker, P. I., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., and Altshuler, D. (2005). Efficiency and power in genetic association studies. Nat. Genet. 37, 1217-1223. doi: 10.1038/ng1669.
12. De Los Campos, G., Gianola, D., and Allison, D. B. (2010). Predicting genetic predisposition in humans: the promise of whole-genome markers. Nat. Rev. Genet. 11, 880-886. doi: 10.1038/nrg2898.
13. Duan, S., Bleibel, W. K., Huang, R. S., Shukla, S. J., Wu, X., Badner, J. A., et al. (2007). Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67, 5425-5433. doi: 10.1158/0008-5472.CAN-06-4431.
14. Estey, E. H. (2012). Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87, 89-99. doi: 10.1002/ajh.22246.
15. Ewer, S. M., and Ewer, M. S. (2009). Anthracycline cardiotoxicity: why are we still interested? Oncology (Williston Park) 23, 234-235, 239.
16. Gille, L., and Nohl, H. (1997). Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 23, 775-782. doi: 10.1016/S0891-5849(97)00025-7.
17. Goeman, J. J., and Finos, L. (2012). The inheritance procedure: multiple testing of tree-structured hypotheses. Stat. Appl. Genet. Mol. Biol. 11:11. doi: 10.1515/1544-6115.1554.
18. Goeman, J. J., Van De Geer, S. A., and Van Houwelingen, H. C. (2006). Testing against a high dimensional alternative. J. R. Stat. Soci. Series B (Stat. Methodol.) 68, 477-493. doi: 10.1111/j.1467-9868.2006.00551.x.
19. Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10, 579-599. doi: 10.2217/pgs.09.7.
20. Han, X., Li, Y., Huang, J., Zhang, Y., Holford, T., Lan, Q., et al. (2012). Identification of predictive pathways for non-hodgkin lymphoma prognosis. Cancer Inform. 9, 281-292. doi: 10.4137/CIN.S6315.
21. Hattersley, A. T., and McCarthy, M. I. (2005). What makes a good genetic association study? Lancet 366, 1315-1323. doi: 10.1016/S0140-6736(05)67531-9.
22. Ioannidis, J. P. (2008). Why most discovered true associations are inflated. Epidemiology 19, 640-648. doi: 10.1097/EDE.0b013e31818131e7.
23. Jensen, C. J., Oldfield, B. J., and Rubio, J. P. (2009). Splicing, cis genetic variation and disease. Biochem. Soc. Trans. 37, 1311-1315. doi: 10.1042/BST0371311.
24. Kim, H. P., Bernard, L., Berkowitz, J., Nitta, J., and Hogge, D. E. (2012). Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia. Cytometry B. Clin. Cytom. 82, 283-294. doi: 10.1002/cyto.b.21028.
25. Kostrzewa-Nowak, D., Paine, M. J., Wolf, C. R., and Tarasiuk, J. (2005). The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br. J. Cancer 93, 89-97. doi: 10.1038/sj.bjc.6602639.
26. Kraft, P., and Hunter, D. J. (2009). Genetic risk prediction-are we there yet? N. Engl. J. Med. 360, 1701-1703. doi: 10.1056/NEJMp0810107.
27. Lopez-Lopez, E., Martin-Guerrero, I., Ballesteros, J., Pinan, M. A., Garcia-Miguel, P., Navajas, A., et al. (2011). Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 57, 612-619. doi: 10.1002/pbc.23074.
28. McLeod, H. L. (2013). Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339, 1563-1566. doi: 10.1126/science.1234139.
29. Menna, P., Paz, O. G., Chello, M., Covino, E., Salvatorelli, E., and Minotti, G. (2012). Anthracycline cardiotoxicity. Expert Opin. Drug Saf. 11(Suppl. 1), S21-S36. doi: 10.1517/14740338.2011.589834.
30. Miaskowski, C., Dodd, M., Paul, S. M., West, C., Hamolsky, D., Abrams, G., et al. (2013). Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS ONE 8:e60164. doi: 10.1371/journal.pone.0060164.
31. Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., et al. (2011). Consequences of POR mutations and polymorphisms. Mol. Cell. Endocrinol. 336, 174-179. doi: 10.1016/j.mce.2010.10.022.
32. Ober, C., and Vercelli, D. (2011). Gene-environment interactions in human disease: nuisance or opportunity? Trends Genet. 27, 107-115. doi: 10.1016/j.tig.2010.12.004.
33. Ott, C. J., Blackledge, N. P., Leir, S. H., and Harris, A. (2009). Novel regulatory mechanisms for the CFTR gene. Biochem. Soc. Trans. 37, 843-848. doi: 10.1042/BST0370843.
34. Pan, W. (2009). Asymptotic tests of association with multiple SNPs in linkage disequilibrium. Genet. Epidemiol. 33, 497-507. doi: 10.1002/gepi.20402.
35. Peters, E. J., Motsinger-Reif, A., Havener, T. M., Everitt, L., Hardison, N. E., Watson, V. G., et al. (2011). Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 12, 1407-1415. doi: 10.2217/pgs.11.92.
36. Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., and Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909. doi: 10.1038/ng1847.
37. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575. doi: 10.1086/519795.
38. Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., Sullivan, P. F., et al. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752. doi: 10.1038/nature08185.
39. Rajic, V., Aplenc, R., Debeljak, M., Prestor, V. V., Karas-Kuzelicki, N., Mlinaric-Rascan, I., et al. (2009). Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk. Lymphoma 50, 1693-1698. doi: 10.1080/10428190903177212.
40. R-Development-Core-Team. (2011). R: A Language and Environment for Statistical Computing. Vienna: F.F.S. Computing.
41. Sawyer, D. B., Peng, X., Chen, B., Pentassuglia, L., and Lim, C. C. (2010). Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog. Cardiovasc. Dis. 53, 105-113. doi: 10.1016/j.pcad.2010.06.007.
42. Stringer, S., Wray, N. R., Kahn, R. S., and Derks, E. M. (2011). Underestimated effect sizes in GWAS: fundamental limitations of single SNP analysis for dichotomous phenotypes. PLoS ONE 6:e27964. doi: 10.1371/journal.pone.0027964.
43. Trevino, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., et al. (2009). Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972-5978. doi: 10.1200/JCO.2008.20.4156.
44. Urbach, D., Lupien, M., Karagas, M. R., and Moore, J. H. (2012). Cancer heterogeneity: origins and implications for genetic association studies. Trends Genet. 28, 538-543. doi: 10.1016/j.tig.2012.07.001.
45. Venables, W. N., and Ripley, B. D. (2002). Modern Applied Statistics with S. 4th Edn. New York, NY: Springer.
46. Visscher, H., Ross, C. J., Rassekh, S. R., Barhdadi, A., Dube, M. P., Al-Saloos, H., et al. (2012). Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30, 1422-1428. doi: 10.1200/JCO.2010.34.3467.
47. Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., and Ratain, M. J. (2012). Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14, 23-34. doi: 10.1038/nrg3352.
48. Wojnowski, L., Kulle, B., Schirmer, M., Schluter, G., Schmidt, A., Rosenberger, A., et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112, 3754-3762. doi: 10.1161/CIRCULATIONAHA.105.576850.
49. Yang, J., Benyamin, B., McEvoy, B. P., Gordon, S., Henders, A. K., Nyholt, D. R., et al. (2010). Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565-569. doi: 10.1038/ng.608.
50. Yeh, E. T., and Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231-2247. doi: 10.1016/j.jacc.2009.02.050.
51. Zhang, X., Li, L., Ding, X., and Kaminsky, L. S. (2011). Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439. doi: 10.1124/dmd.111.038836.
52. Zordoky, B. N., Anwar-Mohamed, A., Aboutabl, M. E., and El-Kadi, A. O. (2010). Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol. Appl. Pharmacol. 242, 38-46. doi: 10.1016/j.taap.2009.09.012.